Summary:
Click image to enlarge
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Qualified Participants Must:
• Diagnosis of HS for at least 6 months prior to screening visit.
•
Age 12 or older at time of screening.
•
Have active HS skin symptoms on at least two areas of the body.
Qualified Participants May Receive:
You will be compensated for your time and effort for participating in this Study, including filling out the electronic diary between visits. You will be paid $200 for each completed Study visit.
You will not be paid for any visits that have not been completed or missed. You will be paid following each completed visit.